Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease – a perspective

References

• USDHHS, National Center for Health StatisticsSecond National Health and Nutrition Examination Survey (NHANES II)Hyattsville MDCDC19761980
   Google Scholar
• USDHHS, National Center for Health StatisticsSecond National Health and Nutrition Examination Survey (Continuous NHANES)Hyattsville MDCDC19992002
   Google Scholar
• YoungFCapewellSFordESCritchleyJACoronary mortality declines in the US between 1980 and 2000. Quantifying the contributions from primary and secondary preventionAm J Prev Med20103922823420709254
   PubMed Web of Science ®Google Scholar
• FordESCapewellSCoronary heart disease mortality among young adults in the US from 1980 to 2002: concealed leveling or mortality ratesJ Am Coll Cardiol2007502128213218036449
   PubMed Web of Science ®Google Scholar
• CDC National Center for Health StatisticsCDC mortality data, 2008: CDC latest release mortality data, 2005 www.cdc.gov/nchs/fastats/deaths.htmAccessed 2010 Oct 7
   Google Scholar
• SackerAHeadJBartleyMImpact of coronary heart disease on health functioning in an aging population: are there differences according to socioeconomic positionPsychosom Med20087013314018256343
   PubMed Web of Science ®Google Scholar
• AllenderSScarboroughPPetoVEuropean cardiovascular disease statistics 2008European Heart Network, 2008 www.heart-stats.org/uploads/documents%5Cproof30NOV2007.pdfAccessed 2010 Oct 7
   Google Scholar
• WHO Statistical Information SystemMortality data for ICD 10 codings www.who.int/whosis/database/mort/download/ftp/morticd10.zipAccessed 2010 Oct 7
   Google Scholar
• RidkerPMDanielsonEFonsecaFAfor JUPITER Study GroupRosuvastatin to prevent vascular events in men and women with elevated C-reactive proteinN Engl J Med20083592195220718997196
   PubMed Web of Science ®Google Scholar
• ThompsonDPepysMBWoodSPThe physiological structure of human C-reactive protein and its complex with phosphocholineStructure1999716917710368284
   PubMed Web of Science ®Google Scholar
• PepysMBHirschfieldGMC-reactive protein: a critical updateJ Clin Invest20031111805181212813013
   PubMed Web of Science ®Google Scholar
• RidkerPMCushmanMStampferMJTracyRPHennekensCHInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy menN Engl J Med19973369739799077376
   PubMed Web of Science ®Google Scholar
• HanssonGKLibbyPThe immune response in atherosclerosis: a double-edged swordNat Rev Immunol2006650851916778830
   PubMed Web of Science ®Google Scholar
• HwangSJBallantyneCMSharrettARCirculating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) studyCirculation199796421942259416885
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNStampferMJHennekensCHPlasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy menCirculation20001011767177210769275
   PubMed Web of Science ®Google Scholar
• RossRAtherosclerosis–an inflammatory diseaseN Engl J Med19993401151269887164
   PubMed Web of Science ®Google Scholar
• LibbyPRidkerPMInflammation and atherothrombosis: from population biology and bench research to clinical practiceJ Am Coll Cardiol200648A3346
   Web of Science ®Google Scholar
• HanssonGKInflammation, atherosclerosis, and coronary artery diseaseN Engl J Med20053521685169515843671
   PubMed Web of Science ®Google Scholar
• LibbyPNahrendorfMPittetMJSwirskiFKDiversity of denizens of the atherosclerotic plaque: not all monocytes are created equalCirculation20081173168317018574058
   PubMed Web of Science ®Google Scholar
• MachFSchoenbeckUBonnefoyJYPoberJLibbyPActivation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40. Induction of collagenase, stromelysin, and tissue factorCirculation1997963963999244201
   PubMed Web of Science ®Google Scholar
• SpagnoliLGBonannoEMaurielloAMulticentric inflammation in epicardial coronary arteries of patients dying of acute myocardial infarctionJ Am Coll Cardiol2002401579158812427409
   PubMed Web of Science ®Google Scholar
• AbbateABonannoEMaurielloAWidespread myocardial inflammation and infarct-related artery patencyCirculation2004110465015210601
   PubMed Web of Science ®Google Scholar
• LombardoABiasucciLMLanzaGAInflammation as a possible link between coronary and carotid plaque instabilityCirculation20041093158316315184282
   PubMed Web of Science ®Google Scholar
• NakajimaTSchulteSWarringtonKJT-cell-mediated lysis of endothelial cells in acute coronary syndromesCirculation200210557057511827921
   PubMed Web of Science ®Google Scholar
• BlakeGJRidkerPMInflammatory bio-markers and cardiovascular risk predictionJ Intern Med200225228329412366601
   PubMed Web of Science ®Google Scholar
• EspositoKGiuglianoDDiet and inflammation: a link to metabolic and cardiovascular diseasesEur Heart J200627152016219650
   PubMed Web of Science ®Google Scholar
• FreedmanJELoscalzoJPlatelet–monocyte aggregates: bridging thrombosis and inflammationCirculation20021052130213211994242
   PubMed Web of Science ®Google Scholar
• SteinhublSRPlatelets as mediators of inflammationHematol Oncol Clin North Am20072111512117258122
   PubMed Web of Science ®Google Scholar
• NettletonJAMatijevicNFollisJLFolsomARBoerwinkleEAssociations between dietary patterns and flow cytometry-measured biomarkers of inflammation and cellular activation in the Atherosclerosis Risk in Communities (ARIC) Carotid Artery MRI StudyAtherosclerosis201021226026720537646
   PubMed Web of Science ®Google Scholar
• LibbyPInflammation in atherosclerosisNature200242086887412490960
   PubMed Web of Science ®Google Scholar
• RidkerPMTesting the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)J Thromb Haemost20097Suppl 133233919630828
   PubMed Web of Science ®Google Scholar
• BrugalettaSBiasucciLMPinnelliMNovel anti-inflammatory effect of statins: reduction of CD4+CD28null T lymphocyte frequency in patients with unstable anginaHeart20069224925016415193
   PubMed Web of Science ®Google Scholar
• TaubesGDoes Inflammation cut to the heart of the matterScience200229624224511951014
   PubMed Web of Science ®Google Scholar
• WilliamsKJTabasIAtherosclerosis and inflammationScience200229752152212143880
   PubMed Web of Science ®Google Scholar
• RidkerPMHennekensCHBuringJERifaiNC-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in womenN Engl J Med200034283684310733371
   PubMed Web of Science ®Google Scholar
• PackardRRSLibbyPInflammation in atherosclerosis: from vascular biology to biomarker discovery and risk predictionClin Chem200843243818160725
   PubMed Web of Science ®Google Scholar
• AltmanRRisk factors in coronary atherosclerosis ather-inflammation: the meeting pointThrombosis J200314
   Google Scholar
• VorchheimerDAFusterVInflammatory markers in coronary artery disease. Let prevention douse the flamesJAMA20012862154215611694158
   PubMed Web of Science ®Google Scholar
• RossRThe pathogenesis of atherosclerosis: a perspective for the 1990sNature19933628018098479518
   PubMed Web of Science ®Google Scholar
• CybulskyMIGimbroneMAJrEndothelial expression of a mono-nuclear leukocyte adhesion molecule during atherogenesisScience19912517887911990440
   PubMed Web of Science ®Google Scholar
• BonettiPOLermanLOLermanAEndothelial dysfunction: a marker of atherosclerotic riskArterioscler Thromb Vasc Biol20032316817512588755
   PubMed Web of Science ®Google Scholar
• LiuzzoGBiasucciLMGallimoreJLThe prognostic value of C-reactive protein and serum amyloid A protein in severe unstable anginaN Engl J Med19943314174247880233
   PubMed Web of Science ®Google Scholar
• BiasucciLMVitelliALiuzzoGElevated level of interleukin-6 in unstable anginaCirculation1996948748778790019
   PubMed Web of Science ®Google Scholar
• LibbyPRidkerPMMaseriAInflammation and atherosclerosisCirculation20021051135114311877368
   PubMed Web of Science ®Google Scholar
• WuKKAleksicNBallantyneChMAhnChJunejaHBoerwinkleEInteraction between soluble thrombomodulin and Intercellular Adhesion Molecule-1 in predicting risk of coronary heart diseaseCirculation20031071729173212668515
   PubMed Web of Science ®Google Scholar
• BhattDLTopolEJNeed to test the arterial inflammation hypothesisCirculation200210613614012093783
   PubMed Web of Science ®Google Scholar
• KereiakesDJThe fire that burns within. C-reactive proteinCirculation200310737337412551855
   PubMed Web of Science ®Google Scholar
• RidkerPMHigh-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefitAm Heart J2004148S192615211329
   PubMed Web of Science ®Google Scholar
• DhingraRGonaPNamB-HC-reactive protein, inflammatory conditions, and cardiovascular disease riskAm J Med20071201054106218060926
   PubMed Web of Science ®Google Scholar
• GustafsonBHammarstedtAAnderssonCXSmithUInflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosisAtheroscler Thromb Vasc Biol20072722762283
   PubMed Web of Science ®Google Scholar
• LiuYYuHZhangYZhaoYTLRs are important inflammatory factors in atherosclerosis and may be a therapeutic targetMed Hypoth200870314316
   Web of Science ®Google Scholar
• ViraniSSPolsaniVRNambiZVNovel markers of inflammatioin in atherosclerosisCurr Atheroscler Rep20081016417018417072
   PubMed Web of Science ®Google Scholar
• PeisajovichAMarnellLMoldCDu ClosTWC-reactive protein at the interface between innate immunity and inflammationExpert Rev Clin Immunol2008437939020476927
   PubMed Web of Science ®Google Scholar
• IkonomidisIStamatelopoulosKLekakisJVamvakouGDKremastinosDTInflammatory and non-invasive vascular markers: the multimarker approach for risk stratification in coronary artery diseaseAtherosclerosis200819931118378239
   PubMed Web of Science ®Google Scholar
• OtakeHShiteJShinkeTRelation between plasma adiponectin, high sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndromeAm J Cardiol20081011718157956
   PubMed Web of Science ®Google Scholar
• ChamberlainJFrancisSBrookesZInterleukin-1 regulates multiples atherogenic mechanisms in response to fat feedingPLoS ONE20094e507319347044
   PubMed Web of Science ®Google Scholar
• LibbyPOkamotoYRochaVZFolcoEInflammation in atherosclerosis: transition from theory to practiceCirc J20107421322020065609
   PubMed Web of Science ®Google Scholar
• IkedaUInflammation and coronary artery diseaseCurr Vasc Pharmacol20031657015320854
   PubMedGoogle Scholar
• HeinischRHZanettiCRCominFFernandesJLRamiresJASerranoCVJrSerial changes in plasma levels of cytokines in patients with coronary artery diseaseVasc Health Risk Manag2005124525017319110
   PubMedGoogle Scholar
• RidkerPMInflammation, high-sensitivity C-reactive protein, and vascular protectionTex Heart Inst J201037404120200625
   PubMed Web of Science ®Google Scholar
• CurtissLKReversing atherosclerosisN Eng J Med200936011441146
   PubMed Web of Science ®Google Scholar
• TillettWSFrancisTJrSerological reactions in pneumonia with a non-protein fraction of pneumococcusJ Exp Med19305256157119869788
   PubMedGoogle Scholar
• NorataGDMarchesiPPulakazhiVKDeficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosisCirculation200912069970819667236
   PubMed Web of Science ®Google Scholar
• HanssonGKLibbyPSchönbeckUYanZQInnate and adaptive immunity in the pathogenesis of atherosclerosisCirc Res20029128129112193460
   PubMed Web of Science ®Google Scholar
• Abou-RayaAAbou-RayaSInflammation: a pivotal link between autoimmune diseases and atherosclerosisAutoimmun Rev2006533133716782558
   PubMed Web of Science ®Google Scholar
• SunJHartvigsenKChouM-YDeficiency of antigen-presenting cell invariant chain reduces atherosclerosis in miceCirculation201012280882020697023
   PubMed Web of Science ®Google Scholar
• OkemefunaAINanRMillerAGorJPerkinsSJComplement factor H binds at two independent sites to C-reactive protein in acute phase concentrationsJ Biol Chem20102851053106519850925
   PubMed Web of Science ®Google Scholar
• Bodman-SmithKBMelendezAJCampbellIHarrisonPTAllenJMRaynesJGC-reactive protein-mediated phagocytosis and phospholipase D signaling through the high-affinity receptor for immunoglobulin G (FcγRI)Immunology200220725226012383205
   PubMed Web of Science ®Google Scholar
• GabayCKushnerIAcute-phase proteins and other systemic responses to inflammationN Eng J Med1999340448454
   PubMed Web of Science ®Google Scholar
• VigushinDMPepysMBHawkinsPNMetabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and diseaseJ Clin Invest199391135113578473487
   PubMed Web of Science ®Google Scholar
• LauDCDhillonBYanHSzmitkoPEVermaSAdipokines: molecular links between obesity and atheroslcerosisAm J Physiol Heart Circ Physiol2005288H2031204115653761
   PubMed Web of Science ®Google Scholar
• BrullDJSerranoNZitoFHuman CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart diseaseArterioscler Thromb Vasc Biol2003232063206912842840
   PubMed Web of Science ®Google Scholar
• KathiresanSLarsonMGVasanRSContribution of clinical correlates and 13 C-reactive protein gene polymorphisms to inter-individual variability in serum C-reactive protein levelCirculation20061131415142316534007
   PubMed Web of Science ®Google Scholar
• ShahTNewcombePSmeethLAncestry as a determinant of mean population C-reactive protein values: implications for cardiovascular risk predictionCirc Cardiovasc Genet2010343644420876875
   PubMedGoogle Scholar
• RückerlRGrevenSLjungmanPfor the Airgene studyAir pollution and inflammation (interleukin-6, C-reactive protein, fibrinogen) in myocardial infarction survivorsEnviron Health Perspect20071151072108017637925
   PubMed Web of Science ®Google Scholar
• KingDEEganBMWoolsonRFMainousAGIIIAl-SolaimanYJesriAEffect of a high-fiber diet vs a fiber-supplemented diet on C-reactive protein levelArch Intern Med200716750250617353499
   PubMed Web of Science ®Google Scholar
• BoSDurazzoMGuidiSDietary magnesium and fiber intakes and inflammatory and metabolic indicators in middle-aged subjects from a population-based cohortAm J Clinical Nutrition2006841062106917093158
   PubMed Web of Science ®Google Scholar
• KingDEMainousAGIIIEganBMWoolsonRFGeeseyMEEffect of psyllium fiber supplementation on C-reactive protein: the trial to reduce inflammatory markers (TRIM)Ann Fam Med2008610010618332401
   PubMed Web of Science ®Google Scholar
• AjaniUAFordESMokdadAHDietary fiber and C-reactive protein: findings from national health and nutrition examination survey dataJ Nutr20041341181118515113967
   PubMed Web of Science ®Google Scholar
• ZampelasAPanagiotakosDBPitsavosCAssociations between coffee consumption and inflammatory markers in healthy persons: the ATTICA studyAm J Clin Nutr20048086286715447891
   PubMed Web of Science ®Google Scholar
• CavicchiaPPSteckSEHurleyTFA new dietary inflammatory index predicts interval changes in serum high-sensitivity C-reactive proteinJ Nutr20091392365237219864399
   PubMed Web of Science ®Google Scholar
• MastersRCLieseADHaffnerSMWagenknechtLEHanleyAJWhole and refined grain intakes are related to inflammatory protein concentrations in human plasmaJ Nutr201014058759420089789
   PubMed Web of Science ®Google Scholar
• EsmaillzadahAKimiagarMMehrabiYAzadbakhtLHuFBWillettWCFruit and vegetable intakes, C-reactive protein, and the metabolic syndromeAm J Clin Nutr2006841489249717158434
   PubMed Web of Science ®Google Scholar
• MicallefMAMunroIAGargMLAn inverse relationship between plasma n-3 fatty acids and C-reactive protein in healthy individualsEur J Clin Nutr2009631154115619352379
   PubMed Web of Science ®Google Scholar
• YenMLYangCYYenBLIncreased high sensitivity C-reactive protein and neutrophil count are related to increased standard cardiovascular risk factors in healthy Chinese menInt J Cardiol200611019119816305810
   PubMed Web of Science ®Google Scholar
• DaneshJWheelerJGHirschfieldGMC-reactive protein and other circulating markers of inflammation in the prediction of coronary heart diseaseN Engl J Med20043501387139715070788
   PubMed Web of Science ®Google Scholar
• FaberDRvan der GraafYWesterinkJVisserenFLJIncreased visceral adipose tissue mass is associated with increased C-reactive protein in patients with manifest vascular diseasesAtherosclerosis201021227428020494358
   PubMed Web of Science ®Google Scholar
• ImhofAFroehlichMBrennerHEffect of alcohol consumption on systemic markers of inflammationLancet200135776376711253971
   PubMed Web of Science ®Google Scholar
• AlbertMAGlynnRJRidkerPMAlcohol consumption and plasma concentration of C-reactive proteinCirculation200310744344712551869
   PubMed Web of Science ®Google Scholar
• DreonDMSlavinJLPhinneySDOral contraceptive use and increased plasma concentration of C-reactive proteinLife Sci2003731245125212850240
   PubMed Web of Science ®Google Scholar
• FrohlichMMuhlbergerNHankeHMarkers of inflammation in women on different hormone replacement therapiesAnn Med20033535336112952022
   PubMed Web of Science ®Google Scholar
• BlackSKushnerISamolsDC-reactive proteinJ Biol Chem2004279484874849015337754
   PubMed Web of Science ®Google Scholar
• McDadeTWRutherfordJNAdairLKuzawaCPopulation differences in associations between C-reactive protein concentration and adiposity: comparison of young adults in the Philippines and the United StatesAm J Clin Nutr2009891237124519225115
   PubMed Web of Science ®Google Scholar
• RussellAICunninghame GrahamDSShepherdCPolymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosusHum Mol Genet20041313714714645206
   PubMed Web of Science ®Google Scholar
• JönsenAGunnarssonIGullstrandBAssociation between SLE nephritis and polymorphic variants of the CRP and Fcgamma;RIIIa genesRheumatology (Oxford)2007461417142117596285
   PubMed Web of Science ®Google Scholar
• EdbergJCWuJLangefeldCDGenetic variation in the CRP promoter: association with systemic lupus erythematosus (SLE)Hum Mol Genet2008171147145518182444
   PubMed Web of Science ®Google Scholar
• GrafJScherzerRGrunfeldCImbodenJLevels of C-reactive protein associated with high and very high cardiovascular risk are prevalent in patients with rheumatoid arthritisPLoS ONE20094e624219606218
   PubMed Web of Science ®Google Scholar
• CoventryBJAshdownMLQuinnMAMarkovicSNYatomi-ClarkeSLRobinsonAPCRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting toolJ Transl Med2009710219948067
   PubMed Web of Science ®Google Scholar
• Morin-PapunenLRautioKRuokonenAHedbergPPuukkaMTapanainenJSMetformin reduces serum C-reactive protein levels in women with polycystic ovary syndromeJ Clin Endocrinol Metab2003884649465414557435
   PubMed Web of Science ®Google Scholar
• TosiFDorizziRCastelloRBody fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndromeEur J Endocrinol200916173774519713424
   PubMed Web of Science ®Google Scholar
• SathyapalanTKilpatrickESCoadyAMAtkinSLThe effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled studyJ Clin Endocrinol Metab20099410310818940877
   PubMed Web of Science ®Google Scholar
• HoegerKMPolycystic ovary syndrome, inflammation and statins: do we have the right targetJ Clin Endocrinol Metab200994353719126632
   PubMed Web of Science ®Google Scholar
• De BeerFSoutarAKBaltzMLTraynerIMFeinsteinAPepysMBLow density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive proteinJ Exp Med19821562302427086355
   PubMed Web of Science ®Google Scholar
• ZhangYXCliffWJSchoeflGIHigginsGCoronary C-reactive protein distribution: its relation to development of atherosclerosisAtherosclerosis199914537537910488966
   PubMed Web of Science ®Google Scholar
• PasceriVWillersonJTYehETDirect proinflammatory effect of C-reactive protein on human endothelial cellsCirculation20001022165216811056086
   PubMed Web of Science ®Google Scholar
• TorzewskiMRistCMortensenRFC-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesisArterioscler Thromb Vasc Biol2000202094209910978254
   PubMed Web of Science ®Google Scholar
• DevarajSDavisBSimonSIJialalICRP promotes monocyte-endothelial cell adhesion via Fcgamma;receptors in human aortic endothelial cells under static and shear flow conditionsAm J Physiol Heart Circ Physiol2006291H1170117616603696
   PubMed Web of Science ®Google Scholar
• RockerCManolovDEKuzmenkinaEVAffinity of C-reactive protein toward FcgammaRI is strongly enhanced by the gamma-chainAm J Pathol200717075576317255341
   PubMed Web of Science ®Google Scholar
• SchwartzROsborne-LawrenceSHahnerLC-reactive protein downregulates endothelial NO synthase and attenuates reendothelialization in vivo in miceCirc Res20071001452145917446434
   PubMed Web of Science ®Google Scholar
• SzmitkoPEVermaSC-reactive protein and reendothelialization: NO involvementCirc Res20071001405140717525379
   PubMed Web of Science ®Google Scholar
• XingDHageFGChenYFExaggerated neointima formation in human C-reactive protein transgenic mice is IgG Fc receptor type 1 (Fc gamma RI)-dependentAm J Pathol2008172223018063701
   PubMed Web of Science ®Google Scholar
• SalioMChimentiSde AngelisNCardioprotective function of the long pentraxin PTX3 in acute myocardial infarctionCirculation20081171055106418268142
   PubMed Web of Science ®Google Scholar
• Van VréEABultHHoymansVYvan TendelooFIVrintsCJBosmansJMHuman C-reactive protein activates monocyte-derived dendritic cells and induces dendritic cell-mediated T-cell activationArterioscler Thromb Vasc Biol20082851151818218989
   PubMed Web of Science ®Google Scholar
• FujitaYKakinoANishimichiNOxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effectsClin Chem20095528529419074514
   PubMed Web of Science ®Google Scholar
• FilepJGPlatelets affect the structure and function of C-reactive proteinCirc Res200910510911119608987
   PubMed Web of Science ®Google Scholar
• JinCLuLZhangRYAssociation of serum glycated albumin, C-reactive protein and ICAM-1 levels with diffuse coronary artery disease in patients with type 2 diabetes mellitusClin Chim Acta2009408454919615354
   PubMed Web of Science ®Google Scholar
• RidkerPMC-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular diseaseClin Chem20095520921519095723
   PubMed Web of Science ®Google Scholar
• GelukCAPostWJHillegeHLC-reactive protein and angiographic characteristics of stable and unstable coronary artery disease: data from the prospective PREVEND cohortAtherosclerosis200819637238217157301
   PubMed Web of Science ®Google Scholar
• NabataAKurokiMUebaHC-reactive protein induces endothelial cell apoptosis and matrix metalloproteinase-9 production in human mononuclear cells: implications for the destabilization of atherosclerotic plaqueAtherosclerosis200819612913517531242
   PubMed Web of Science ®Google Scholar
• SciricaBMCannonCPSabatineMSConcentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular deathClin Chem20095526527319074516
   PubMed Web of Science ®Google Scholar
• SciricaBMMorrowDACannonCPThrombolysis in Myocardial Infarction (TIMI) Study GroupClinical application of C-reactive protein across the spectrum of acute coronary syndromesClin Chem2007531800180717717132
   PubMed Web of Science ®Google Scholar
• SciricaBMMorrowDAIs C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still outCirculation20061132128213416651484
   PubMed Web of Science ®Google Scholar
• VermaSDevarajSJialalIIs C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosisCirculation20061132135215016671184
   PubMed Web of Science ®Google Scholar
• JialalIVermaSDevarajSInhibition of endothelial nitric oxide synthase by C-reactive protein: clinical relevanceClin Chem20095520620819095724
   PubMed Web of Science ®Google Scholar
• GuanHWangPHuiREdinMLZeldinDCWangDWAdeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in ratsClin Chem20095527428419056836
   PubMed Web of Science ®Google Scholar
• RadjeshJBisoendialSBoekholdtMVergeerMStroesESGKasteleinJJPC-reactive protein is a mediator of cardiovascular diseaseEur Heart J2010312087209120685682
   PubMed Web of Science ®Google Scholar
• SinclairKABogartABuchwaldDHendersonJAThe prevalence of metabolic syndrome and associated risk factors in Northern Plains and Southwest American IndiansDiabetes Care2010923 [Epub ahead of print]
   Web of Science ®Google Scholar
• KearneyMTTargeting the endothelium to prevent diabetes-related atherosclerosisDiab Vasc Dis Res2010717720699387
   PubMed Web of Science ®Google Scholar
• FordESGilesWHMyersGLManninoDMPopulation distribution of high-sensitivity C-reactive protein among US men: findings from national health and nutrition examination survey 1999–2000Clin Chem200349686690 http://www.clinchem.org/cgi/content/full/49/4/68612651834
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionNHANES 1999–2000 public data release file documentation http://www.cdc.gov/nchs/data/nhanes/gendoc.pdfAccessed 2010 Oct 18
   Google Scholar
• RifaiNRidkerPMPopulation distributions of C-reactive protein in apparently healthy men and women in the United States: implication for clinical interpretationClin Chem20034966666912651826
   PubMed Web of Science ®Google Scholar
• WoloshinSSchwartzLMDistribution of C-reactive protein values in the United StatesN Eng J Med200535216111613
   PubMed Web of Science ®Google Scholar
• KushnerIRzewnickiWSamolsDWhat does minor elevation of C-reactive protein signify?Am J Med2006119166.e17166.e2816443421
   PubMedGoogle Scholar
• KaoPCShieshS-CWuTJSerum C-reactive protein as a marker for wellness assessmentAnn Clin Lab Sci20063616316916682512
   PubMed Web of Science ®Google Scholar
• KoenigWSundMFrohlichMC-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992Circulation1999992372429892589
   PubMed Web of Science ®Google Scholar
• MillerMZhanMHavasSHigh attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination SurveyArch Intern Med20051652063206816216995
   PubMedGoogle Scholar
• GreenfieldJRSamarasKJenkinsABObesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influencesCirculation20041093022302815184288
   PubMed Web of Science ®Google Scholar
• CurrieCJPooleCDConwayPEvaluation of the association between the first observation and the longitudinal change in C-reactive protein, and all-cause mortalityHeart20089445746217761503
   PubMed Web of Science ®Google Scholar
• MarsikCKazemi-ShiraziLSchickbauerTC-reactive protein and all-cause mortality in a large hospital-based cohortClin Chem20085434334918156283
   PubMed Web of Science ®Google Scholar
• KravitzBACorradaMMKawasCHHigh levels of serum C-reactive protein are associated with greater risk of all-cause mortality, but not dementia, in the oldest-old: results from the 90+ studyJ Am Ger Soc200957641646
   PubMed Web of Science ®Google Scholar
• WasselCLBarrett-ConnorELaughlinGAAssociation of circulating C-reactive protein and interleukin-6 with longevity into the 80s and 90s: The Rancho Bernardo StudyJ Clin Endocrinol Metab2010954748475520660034
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNRoseLBuringJECookNRComparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular eventsN Engl J Med20023471557156512432042
   PubMed Web of Science ®Google Scholar
• DiazJJArguellesJMalagaIC-reactive protein is elevated in the offspring of parents with essential hypertensionArch Dis Child20079230430817158147
   PubMed Web of Science ®Google Scholar
• ManciaGde BackerGDominiczakA2007Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)Eur Heart J2007281462153617562668
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonERifaiNGlynnRJValsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trialHypertension200648737916714425
   PubMed Web of Science ®Google Scholar
• SessoHDBuringJERifaiNBlakeGJGazianoJMRidkerPMC-reactive protein and the risk of developing hypertensionJAMA20032902945295114665655
   PubMed Web of Science ®Google Scholar
• SathiyapriyaVNandeeshaHSelvarajNBobbyZAgrawalAPavithranPAssociation between protein-bound sialic acid and high-sensitivity C-reactive protein in essential hypertension: a possible indication of underlying cardiovascular riskAngiology20095972172618388037
   PubMed Web of Science ®Google Scholar
• LandeMBPearsonTAVermilionRPAuingerPFernandezIDElevated blood pressure, race/ethnicity, and C-reactive protein levels in children and adolescentsPediatrics20081221252125719047242
   PubMed Web of Science ®Google Scholar
• BlackGJRifaiNBuringJERidkerPMBlood pressure, C-reactive protein, and risk of future cardiovascular eventsCirculation20031082993299914638538
   PubMed Web of Science ®Google Scholar
• PerticoneFMaioRSciacquaAEnodthelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertensionDiabetes20085716717117928395
   PubMed Web of Science ®Google Scholar
• VardasPEMarketouMECRP in non-dippers: new perspectives and old queriesJ Human Hypertension200822447449
   Web of Science ®Google Scholar
• VeerabhadrappaPDiazKMFeairhellerDLEnhanced blood pressure variability in a high cardiovascular risk group of African Americans: FIT4 Life StudyJ Am Soc Hypertens2010418719520885987
   PubMed Web of Science ®Google Scholar
• IijimaRByrneRANdrepepaGPre-procedural C-reactive protein levels and clinical outcomes after percutaneous coronary interventions with and without abciximab: pooled analysis of four ISAR trialsHeart20099510711218801777
   PubMed Web of Science ®Google Scholar
• IshiiHToriyamaTAoyamaTPrognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimuseluting stents in patients on hemodialysisCirc Cardiovasc Interv2009251351820031768
   PubMed Web of Science ®Google Scholar
• IliodromitisEKKyrzopoulosSParaskevaidisIAIncreased C reactive protein and cardiac enzyme levels after coronary stent implantation. Is there protection by remote ischaemic preconditioningHeart2006921821182616855045
   PubMed Web of Science ®Google Scholar
• KangasniemiOPBiancariFLuukkonenJPreoperative C-reactive protein is predictive of long-term outcome after coronary artery bypass surgeryEur J Cardiothorac Surg20062998398516682213
   PubMed Web of Science ®Google Scholar
• WypasekEUndasASniezek-MaciejewskaMThe increased plasma C-reactive protein and interleukin-6 levels in patients under-going coronary artery bypass grafting surgery are associated with the interleukin-6-174G. C gene polymorphismAnn Clin Biochem20104734334920592333
   PubMed Web of Science ®Google Scholar
• LoBFijnheerRNierichAPBruinsPKalkmanCJC-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularizationAnn Thorac Surg2005791530153515854929
   PubMed Web of Science ®Google Scholar
• KardysIKnetschAMBleuminkGSC-reactive protein and risk of heart failure. The Rotterdam StudyAm Heart J200615251452016923423
   PubMed Web of Science ®Google Scholar
• WilliamsESShahSJAliSNaBYSchillerNBWhooleyMAC-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul StudyEur J Heart Fail200810636918160340
   PubMed Web of Science ®Google Scholar
• BraunwaldEBiomarkers in heart failureN Engl J Med20083582148215918480207
   PubMed Web of Science ®Google Scholar
• BozkurtBMannDLDeswalABiomarkers of inflammation in heart failureHeart Fail Rev20101533134119363700
   PubMed Web of Science ®Google Scholar
• AraujoJPLourencoPAzevedoAPrognostic value of high-sensitivity C-reactive protein in heart failure: a systematic reviewJ Cardiac Fail200915256266
   PubMed Web of Science ®Google Scholar
• CollinsonPOConcentrations of C-reactive protein and B-type natriuretic peptide 30 days after acute coronary syndromes independently predict hospitalization for heart failure and cardiovascular death: just another brick in the wallClin Chem20095520320519095728
   PubMed Web of Science ®Google Scholar
• LamblinNMouquetFHennacheBHigh-sensitivity C-reactive protein: potential adjunct for risk stratification in patients with stable congestive heart failureEur Heart J2005262245225016183690
   PubMed Web of Science ®Google Scholar
• AnandISLatiniRFloreaVGC-reactive protein in heart failure: prognostic value and the effect of valsartanCirculation20051121428143416129801
   PubMed Web of Science ®Google Scholar
• VasanRSSullivanLMRoubenoffRInflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart StudyCirculation20031071486149112654604
   PubMed Web of Science ®Google Scholar
• ConenDRexrodeKMCreagerMARidkerPMPradhanADMetabolic syndrome, inflammation, and risk of symptomatic peripheral artery disease in women: a prospective studyCirculation20091201041104719738135
   PubMed Web of Science ®Google Scholar
• PandeRLPerlsteinTSBeckmanJACreagerMAAssociation of insulin resistance and inflammation with peripheral arterial disease: the National Health and Nutrition Examination Survey, 1999 to 2004Circulation20081181334118559705
   PubMed Web of Science ®Google Scholar
• SchlagerOExnerMMlekuschWC-reactive protein predicts future cardiovascular events in patients with carotid stenosisStroke2007381263126817322087
   PubMed Web of Science ®Google Scholar
• AlbertCMMaJRifaiNProspective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac deathCirculation200241052595259912045163
   PubMed Web of Science ®Google Scholar
• SpoonerPMZipesDPSudden death predictors: an inflammatory associationCirculation20021052574257612045156
   PubMed Web of Science ®Google Scholar
• BeriAContractorTKhasnisAThakurRStatins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effectAm J Cardiovasc Drugs20101015516420524717
   PubMed Web of Science ®Google Scholar
• CorbalánRBraunSPereiraJNavarreteCGonzalezIC-reactive protein and atrial fibrillation: evidence for the presence of inflammation in the perpetuation of the arrhythmiaInt J Cardiol200610832633115985301
   PubMed Web of Science ®Google Scholar
• ConenDRidkerPMEverettBMA multimarker approach to assess the influence of inflammation on the incidence of atrial fibrillation in womenEur Heart J2010311730173620501475
   PubMed Web of Science ®Google Scholar
• MarottSCWNordestgaardBGZachoJDoes elevated C-reactive protein increase atrial fibrillation risk? A mendelian randomization of 47,000 individuals from the general populationJ Am Coll Cardiol20105678979520797493
   PubMed Web of Science ®Google Scholar
• BlangyHSadoulNDoussetBSerum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarctionEuropace2007972472917526509
   PubMed Web of Science ®Google Scholar
• JeevananthamVSinghNIzuoraKD’souzaJPHisDHCorrelation of high sensitivity C-reactive protein and calcific aortic valve diseaseMayo Clin Proc20078217117417290723
   PubMed Web of Science ®Google Scholar
• JonesPDavidsonMSteinEComparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)Am J Cardiol20039215216012860216
   PubMed Web of Science ®Google Scholar
• AyCTenglerTVormittagRVenous thromboembolism a manifestation of the metabolic syndromeHaematologica20079237438017339187
   PubMed Web of Science ®Google Scholar
• QuarckRNawrotTMeynsBDelcroixMC-reactive protein a new predictor of adverse outcome in pulmonary arterial hypertensionJ Am Coll Cardiol2009531211121819341863
   PubMed Web of Science ®Google Scholar
• SoinioMMarniemiJLaaksoMHigh-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up studyDiabetes Care20062932933316443882
   PubMed Web of Science ®Google Scholar
• MarcovecchioMLGianniniCWidmerBC-reactive protein in relation to the development of microalbuminuria in type 1 diabetesDiabetes Care20083197497618235049
   PubMed Web of Science ®Google Scholar
• DehghanAKardysIde MaatMPMGenetic variation, C-reactive protein levels, and incidence of diabetesDiabetes20075687287817327459
   PubMed Web of Science ®Google Scholar
• KahnSEZinmanBHaffnerSMObesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetesDiabetes2006552357236416873701
   PubMed Web of Science ®Google Scholar
• GoldbergRBCytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complicationsJ Clin Endocrinol Metab2009943171318219509100
   PubMed Web of Science ®Google Scholar
• RidkerPMPareGParkerALoci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women’s Genome Health StudyAm J Hum Genet2008821185119218439548
   PubMed Web of Science ®Google Scholar
• RidkerPMBuringJECookNRRifaiNC-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American womenCirculation200310739139712551861
   PubMed Web of Science ®Google Scholar
• Moreno-NavarreteJMMartinez-BarricarteRCatalanVComplement factor H is expressed in adipose tissue in association with insulin resistanceDiabetes20105920020919833879
   PubMed Web of Science ®Google Scholar
• JialalIThe role of the laboratory in the diagnosis of the metabolic syndromeAm J Clin Pathol2009132216116219605808
   PubMed Web of Science ®Google Scholar
• SteinbergerJDanielsSREckelRHAmerican Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and MetabolismCirculation200911962864719139390
   PubMed Web of Science ®Google Scholar
• CornierMADabeleaDHernandezTLThe metabolic syndromeEndocr Rev20082977782218971485
   PubMed Web of Science ®Google Scholar
• SuzukiTKatzRJennyNSMetabolic syndrome, inflammation, and incident heart failure in the elderly: the Cardiovascular Health StudyCirc Heart Fail2008124224819808298
   PubMed Web of Science ®Google Scholar
• YouTNicklasBJDingJThe metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposityJ Gerontol A Biol Sci Med Sci20086341441918426966
   PubMed Web of Science ®Google Scholar
• DaiDFLinJWKaoJHThe effects of metabolic syndrome versus infectious burden on inflammation, severity of coronary atherosclerosis, and major adverse cardiovascular eventsJ Clin Endocrinol Metab2007922532253717426096
   PubMed Web of Science ®Google Scholar
• YeXYuZLiHFrancoOHLiuYLinXDistributions of C-reactive protein and its association with metabolic syndrome in middle-aged and older Chinese peopleJ Am Coll Cardiol2007491798180517466231
   PubMed Web of Science ®Google Scholar
• PitsavosCPanagiotakosDBTzimaNDiet, exercise, and C-reactive protein levels in people with abdominal obesity: the ATTICA epidemiological studyAngiology20075822523317495273
   PubMed Web of Science ®Google Scholar
• DevarajSValleggiDSiegelDJialalIRole of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndromeCurr Atheroscler Rep20101211011820425246
   PubMed Web of Science ®Google Scholar
• WangANakayamaTInflammation, a link between obesity and cardiovascular diseaseMediators Inflamm2010201053591820847813
   PubMed Web of Science ®Google Scholar
• AlyanOMetinFKacmazFHigh levels of high sensitivity C-reactive protein predict the progression of chronic rheumatic mitral stenosisJ Thromb Thrombolysis200928636918622582
   PubMed Web of Science ®Google Scholar
• LeeHMLeTVLopezVAWongNDAssociation of C-reactive protein with reduced forced vital capacity in a nonsmoking US population with metabolic syndrome and diabetesDiabetes Care2008312000200218591402
   PubMed Web of Science ®Google Scholar
• MagnussenHWatzHSystemic inflammation in chronic obstructive pulmonary disease and asthma: relation with comorbiditiesProc Am Thorac Soc2009664865120008868
   PubMedGoogle Scholar
• EickhoffPValipourAKissDDeterminants of systemic vascular function in patients with stable chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20081781211121818836149
   PubMed Web of Science ®Google Scholar
• WahbaIMMakRHObesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney diseaseJ Am Soc Nephrol20072550562
   Web of Science ®Google Scholar
• ChenHYChiuYLHsuSPElevated C-reactive protein level in hemodialysis patients with moderate/severe uremic pruritus: a potential mediator of high overall mortalityQJM201010383784620350963
   PubMed Web of Science ®Google Scholar
• LahrachHGhalimNTakiHSerum paraoxonase activity, high-sensitivity C-reactive protein, and lipoprotein disturbances in end-stage renal disease patients on long-term hemodialysisJ Clin Lipidol200824350
   PubMed Web of Science ®Google Scholar
• LuiMMLamJCMakHK-FC-reactive protein is associated with obstructive sleep apnea independent of visceral obesityChest200913595095619225064
   PubMed Web of Science ®Google Scholar
• SchizaSEMermigkisCPanagiotisC-reactive protein evolution in obstructive sleep apnoea patients under CPAP therapyEur J Clin Invest20104096897520629709
   PubMed Web of Science ®Google Scholar
• ZekaASullivanJRVokonasPSSparrowDSchwartzJInflammatory markers and particulate air pollution: characterizing the pathway to diseaseInt J Epidemiol2006351347135416844771
   PubMed Web of Science ®Google Scholar
• DixonJBHaydenMJLambertGWRaised CRP Levels in obese patients: symptoms of depression have an independent positive associationObesity2008162010201518497736
   PubMed Web of Science ®Google Scholar
• HakAEStehouwerCDBotsMLAssociations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged womenArterioscler Thromb Vasc Biol1999191986199110446082
   PubMed Web of Science ®Google Scholar
• McLaughlinTAbbasiFLamendolaCDifferentiation between obesity and insulin resistance in the association with C-reactive proteinCirculation20021062908291212460870
   PubMed Web of Science ®Google Scholar
• WeeCCMukamalKJHuangADavisRBMcCarthyEPMittlemanMAObesity and C-reactive protein levels among white, black, and hispanic US adultsObesity20081687588018379563
   PubMed Web of Science ®Google Scholar
• SkinnerACSteinerMJHendersonFWPerrinEMMultiple markers of inflammation and weight status: cross-sectional analyses throughout childhoodPediatrics2010125e801e80920194272
   PubMed Web of Science ®Google Scholar
• PuglisiMJFernandezMLModulation of C-reactive protein, tumor necrosis factor α, and adiponectin by diet, exercise, and weight lossJ Nutr20081382293229619022947
   PubMed Web of Science ®Google Scholar
• SacheckJPediatric obesity: an inflammatory conditionJPEN J Parenter Enteral Nutr20083263363718974243
   PubMed Web of Science ®Google Scholar
• RankinJWTurpynADLow carbohydrate, high fat diet increases C-reactive protein during weight lossJ Am Coll Nutr20072616316917536128
   PubMed Web of Science ®Google Scholar
• SelvinEPaynterNPErlingerTPThe effect of weight loss on C-reactive protein: a systematic reviewArch Intern Med2007167313917210875
   PubMed Web of Science ®Google Scholar
• PopeCAIIIParticulate air pollution, C-reactive protein, and cardiac riskEur Heart J2001221149115011440485
   PubMed Web of Science ®Google Scholar
• NicklasBJYouTPahorMBehavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise trainingCMAJ20051721199120915851714
   PubMed Web of Science ®Google Scholar
• GentileMPanicoSRubbaFObesity, overweight, and weight gain over adult life are main determinants of elevated hs- CRP in a cohort of Mediterranean womenEur J Clin Nutr20106487387820517327
   PubMed Web of Science ®Google Scholar
• HamerMSteptoeAProspective study of physical fitness, adiposity, and inflammatory markers in healthy middle-aged men and womenAm J Clin Nutr200989858919056563
   PubMed Web of Science ®Google Scholar
• WelshPPoliseckiERobertsonMUnraveling the directional link between adiposity and inflammation: a bidirectional Mendelian randomization approachJ Clin Endocrinol Metab201095939919906786
   PubMed Web of Science ®Google Scholar
• HubelCAPowersRWSnaedalSC-reactive protein is elevated 30 years after eclamptic pregnancyHypertension2008511499150518413489
   PubMed Web of Science ®Google Scholar
• LauBSharrettSRKingsleyLAC-reactive protein is a marker for human immunodeficiency virus disease progressionArch Intern Med2006166647016401812
   PubMed Web of Science ®Google Scholar
• SurteesPGWainwrightNWJBoekholdtSMLubenRNWarehamNJKhawKTMajor depression, C-reactive protein, and incident ischemic heart disease in healthy men and womenPsychosom Med20087085085518725428
   PubMed Web of Science ®Google Scholar
• RidkerPMHigh-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular diseaseCirculation20011031813181811282915
   PubMed Web of Science ®Google Scholar
• PankowJSFolsomARCushmanMFamilial and genetic determinants of systemic markers of inflammation: the NHLBI family heart studyAtherosclerosis200115468168911257270
   PubMed Web of Science ®Google Scholar
• LeeCCYouNCSongYRelation of genetic variation in the gene coding for C-reactive protein with its plasma protein concentrations: findings from the Women’s Health Initiative Observational CohortClin Chem200955235136019095725
   PubMed Web of Science ®Google Scholar
• Kelley-HedgepethALloyd-JonesDMColvinAEthnic differences in C-reactive protein concentrationsClin Chem2008541027103718403563
   PubMed Web of Science ®Google Scholar
• SmithGDEbrahimSMendelian randomization: can genetic epidemiology contribute to understanding environmental determinants of diseaseInt J Epidemiol20033212212689998
   PubMed Web of Science ®Google Scholar
• ZachoJTybjaerg-HansenAJensenJSGrandePSillesenHNordestgaardBGGenetically elevated C-reactive protein and ischemic vascular diseaseN Engl J Med20083591897190818971492
   PubMed Web of Science ®Google Scholar
• SmithDGCapitalizing on Mendelian randomization to assess the effects of treatmentsJ R Soc Med200710043243517766918
   PubMed Web of Science ®Google Scholar
• SheehanNADidelezVBurtonPRTobinMDMendelian randomisation and causal inference in observational epidemiologyPLoS Med20085e17718752343
   PubMed Web of Science ®Google Scholar
• ElliottPChambersJCZhangWGenetic loci associated with C-reactive protein levels and risk of coronary heart diseaseJAMA2009302374819567438
   PubMed Web of Science ®Google Scholar
• SmithGDEbrahimSMendelian randomization: prospects, potentials, and limitationsInt J Epidemiol200433304215075143
   PubMed Web of Science ®Google Scholar
• EmergingRiskFactorsCollaborationKaptogeSDi AngelantonioELoweGC-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysisLancet201037513214020031199
   PubMed Web of Science ®Google Scholar
• DaneshJKaptogeSMannAGLong-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic reviewPLoS Med20085e7818399716
   PubMed Web of Science ®Google Scholar
• ClarkeREmbersonJRBreezeEBiomarkers of inflammation predict both vascular and non-vascular mortality in older menEur Heart200829800809
   Web of Science ®Google Scholar
• HeikkilaKHarrisRLoweGAssociations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysisCancer Causes Control200920152618704713
   PubMed Web of Science ®Google Scholar
• HabersbergerJEisenhardtSPeterKC-reactive protein measurement and cardiovascular disease. Original TextLancet20109720107820346805
   PubMed Web of Science ®Google Scholar
• JiSRWuYZhuLCell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m)FASEB J20072128429417116742
   PubMed Web of Science ®Google Scholar
• MolinsBPenaEVilahurGMendietaCSlevinMBadimonLC-reactive protein isoforms differ in their effects on thrombus growthArterioscler Thromb Vasc Biol2008282239224618787187
   PubMed Web of Science ®Google Scholar
• EisenhardtSUHabersbergerJMurphyADissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaquesCirc Res200910512813719520972
   PubMed Web of Science ®Google Scholar
• JiSRMaLBaiCJMonomeric C-reactive protein activates endothelial cells via interaction with lipid raft microdomainsFASEB J2009231806181619136614
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNClearfieldMMeasurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary eventsN Engl J Med20013441959196511430324
   PubMed Web of Science ®Google Scholar
• TuzcuEMKapadiaSRTutarEHigh prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasoundCirculation20011032705271011390341
   PubMed Web of Science ®Google Scholar
• RidkerPMCannonCPMorrowDAtorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT – TIMI 22) InvestigatorsC-reactive protein levels and outcomes after statin therapyN Engl J Med2005352202815635109
   PubMed Web of Science ®Google Scholar
• De BeerFCHindCRFoxKMMeasurement of serum C-reactive protein concentration in myocardial ischaemia and infarctionBr Heart J1982472392437059401
   PubMedGoogle Scholar
• HaverkateFThompsonSGPykeSDProduction of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study GroupLancet19973494624669040576
   PubMed Web of Science ®Google Scholar
• NiccoliGBiasucciLMBiscioneCIndependent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable anginaAtherosclerosis200819677978517306806
   PubMed Web of Science ®Google Scholar
• RidkerPMCushmanMStampferMJPlasma concentration of C-reactive protein and risk of developing peripheral vascular diseaseCirculation1998974254289490235
   PubMed Web of Science ®Google Scholar
• NissenSETuzcuEMSchoenhagenPStatin therapy, LDL cholesterol, C-reactive protein, and coronary artery diseaseN Engl J Med2005352293815635110
   PubMed Web of Science ®Google Scholar
• HemingwayHPhilipsonPChenRFitzpatrickNKDamantJEvaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery diseasePLoS Med20107e100028620532236
   PubMed Web of Science ®Google Scholar
• BoekholdtSMHackCESandhuMSC-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993–2003Atherosclerosis200618741542216257408
   PubMed Web of Science ®Google Scholar
• CookNRBuringJERidkerPMThe effect of including C-reactive protein in cardiovascular risk prediction models for womenAnn Intern Med2006145212916818925
   PubMed Web of Science ®Google Scholar
• GenestJMcPhersonRFrohlichJ2009Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendationsCan J Cardiol20092556757919812802
   PubMed Web of Science ®Google Scholar
• AlbertMAGlynnRJRidkerPMPlasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk ScoreCirculation200310816116512835213
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNCookNRBradwinGBuringJENon-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in womenJAMA200529432633316030277
   PubMed Web of Science ®Google Scholar
• ShahTCasasJPCooperJACritical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohortsInt J Epidemiol20093821723118930961
   PubMed Web of Science ®Google Scholar
• WaldDSKasturiratneABestwickJPThe value of C-reactive protein in screening for future coronary heart disease eventsJ Med Screen20091621221420054097
   PubMed Web of Science ®Google Scholar
• LakoskiSGGreenlandPWongNDSchreinerPJCoronary artery calcium scores and risk for cardiovascular events in women classified as “low risk” based on Framingham risk score: the Multi- Ethnic Study of Atherosclerosis (MESA)Arch Intern Med20071672437244218071165
   PubMed Web of Science ®Google Scholar
• RidkerPMBuringJERifaiNCookNRDevelopment and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk ScoreJAMA200729761161917299196
   PubMed Web of Science ®Google Scholar
• WilsonPWPencinaMJacquesPSelhubJD’AgostinoRSrO’DonnellCJC-reactive protein and reclassification of cardiovascular risk in the Framingham Heart StudyCirc Cardiovasc Qual Outcomes20081929720031795
   PubMed Web of Science ®Google Scholar
• RidkerPMPaynterNPRifaiNGazianoJMCookNRC-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for MenCirculation20081182243225118997194
   PubMed Web of Science ®Google Scholar
• CookNRThe case for C-reactive protein as a risk marker for coronary heart diseaseAnn Intern Med201015240620231582
   PubMed Web of Science ®Google Scholar
• CookNRRidkerPMAdvances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measuresAnn Intern Med20095079580219487714
   PubMed Web of Science ®Google Scholar
• RidkerPMMacFadyenJLibbyPGlynnRJRelation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)Am J Cardiol201010620420920599004
   PubMed Web of Science ®Google Scholar
• SlejkoJFPageRLIISullivanPWImplications of Jupiter prevention in adults with elevated C-reactive protein: statin therapy is cost-effective for vascular eventJ Am Coll Cardiol201055A131.E1229
   Google Scholar
• RaoADMilbrandtEBTo JUPITER and beyond: statins, inflammation, and primary preventionCritical Care20101431020497597
   PubMed Web of Science ®Google Scholar
• MacDonaldGPCost-effectiveness of rosuvastatin for primary prevention of cardiovascular events according to Framingham Risk Score in patients with elevated C-reactive proteinJ Am Osteopath Assoc201011042743620805548
   PubMedGoogle Scholar
• DaneshJCollinsRApplebyPPetoRAssociation of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studiesJAMA1998279147714829600484
   PubMed Web of Science ®Google Scholar
• DaneshJWhincupPWalkerMLow grade inflammation and coronary heart disease: prospective study and updated meta-analysesBMJ200032119920410903648
   PubMed Web of Science ®Google Scholar
• NambiVBallantyneCMUtility of statin therapy using high- sensitivity C-reactive protein as an indicator of coronary heart disease riskCurr Atheroscler Rep20057222815683598
   PubMedGoogle Scholar
• RidkerPMHigh-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary preventionAm J Cardiol20039217K22K
   PubMed Web of Science ®Google Scholar
• RocheVFAntihyperlipidemic statins: a self-contained, clinically relevant medicinal chemistry lessonAm J Pharm Educ200569546560
   Web of Science ®Google Scholar
• IstvanESDeisenhoferJStructural mechanism for statin inhibition of HMG-CoA reductaseScience20012921160116411349148
   PubMed Web of Science ®Google Scholar
• HamelinBATurgeonJHydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitorsTrends Pharmacol Sci19981926379509899
   PubMed Web of Science ®Google Scholar
• McTaggartFComparative pharmacology of rosuvastatinAtheroscler Suppl2003491412714032
   PubMed Web of Science ®Google Scholar
• KapurNKRosuvastatin: a highly potent statin for the prevention and management of coronary artery diseaseExpert Rev Cardiovasc Ther2007516117517338662
   PubMedGoogle Scholar
• HoltzmanCWWigginsBSSpinlerSARole of P-glycoprotein in statin drug interactionsPharmacotherapy2006261601160717064205
   PubMed Web of Science ®Google Scholar
• KostapanosMSHaralamposJElisafMSRosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemiaAm J Cardiovasc Drugs201010112820104931
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMCholesterol Treatment Trialists’ (CTT) CollaboratorsEfficacy and safety of cholesterollowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• McKenneyJMPharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risksAm J Cardiol20059660E66E
   PubMed Web of Science ®Google Scholar
• The Galaxy Program http://www.galaxyprogramme.org/about-galaxy/?itemId=2592383Accessed 2010 Oct 18
   Google Scholar
• CrouseJRIIIRaichlenJSRileyWAMETEOR study groupEffect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosisJAMA20072971344135317384434
   PubMed Web of Science ®Google Scholar
• CrouseJRIIIBotsMLEvansGWDoes baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR studyEur J Cardiovasc Prev Rehabil20101722322920038840
   PubMedGoogle Scholar
• KjekshusJApetreiEBarriosVRosuvastatin in older patients with systolic heart failureN Engl J Med20073572248226117984166
   PubMed Web of Science ®Google Scholar
• McMurrayJJVKjekshusJGullestadLCORONA Study GroupEffects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational trial in Heart Failure (CORONA). A retrospective analysisCirculation20091202188219619917888
   PubMed Web of Science ®Google Scholar
• Gissi-HFInvestigatorsTavazziLMaggioniAPMarchioliREffect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trialLancet20083721231123918757089
   PubMed Web of Science ®Google Scholar
• Van der HarstPde BoerRAStatins in the treatment of heart failureCirc Heart Fail2010346246420484198
   PubMed Web of Science ®Google Scholar
• FellströmBCJardineAGSchmiederRERosuvastatin and cardiovascular events in patients undergoing hemodialysisN Eng J Med200937311751182
   Google Scholar
• NarlaVBlahaMJBlumenthalRSMichosEDThe JUPITER and AURORA clinical trials for rosuvastatin in special primary prevention populations: perspectives, outcomes, and consequencesVasc Health Risk Manag200951033104220057896
   PubMedGoogle Scholar
• NissenSENichollsSJSipahiIEffect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trialJAMA20062951556156516533939
   PubMed Web of Science ®Google Scholar
• BallantyneCMRaichlenJSNichollsSASTEROID InvestigatorsEffect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burdenCirculation20081172458246618378607
   PubMed Web of Science ®Google Scholar
• MackWJXiangMSelzerRHHodisHNSerial quantitative coronary angiography and coronary eventsAm Heart J200013999399910827379
   PubMed Web of Science ®Google Scholar
• BuchwaldHMattsJPFitchLLProgram on the Surgical Control of the Hyperlipidemias (POSCH) GroupChanges in sequential coronary arteriograms and subsequent coronary eventsJAMA1992268142914331512911
   PubMed Web of Science ®Google Scholar
• FonsecaFAHIzarMCOPrimary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER StudyExpert Rev Cardiovasc Ther200971041105619764857
   PubMedGoogle Scholar
• LibbyPRidkerPMNovel inflammatory markers of coronary risk: theory versus practiceCirculation19991001148115010484532
   PubMed Web of Science ®Google Scholar
• LemieuxIPascotAPrud’hommeDAlmerasNElevated C-reactive protein: another component of the atherothrombotic profile of abdominal obesityArterioscler Thromb Vasc Biol20012196196711397704
   PubMed Web of Science ®Google Scholar
• RidkerPMRifaiNPfefferMAInflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) InvestigatorsCirculation1998988398449738637
   PubMed Web of Science ®Google Scholar
• RidkerPMJUPITER Study GroupRosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trialCirculation20031082292229714609996
   PubMed Web of Science ®Google Scholar
• RidkerPMFonsecaFAHGenestJJUPITER Trial Study GroupBaseline characteristics of participants in the JUPITER Trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive proteinAm J Cardiol20071001659166418036365
   PubMed Web of Science ®Google Scholar
• De LorgerilMSalenPMartinJLMonjaudIDelayeJMamelleNMediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction – final report of the Lyon Diet Heart StudyCirculation1999997797859989963
   PubMed Web of Science ®Google Scholar
• RemboldCMTo statin or to non-statin in coronary disease – considering absolute risk is the answerAtherosclerosis20071951617064710
   PubMed Web of Science ®Google Scholar
• EverettBMRidkerPMUsing inflammatory biomarkers to guide lipid therapyCurr Cardiovasc Risk Reports200822934
   Google Scholar
• KritekPCampionEWJUPITER Clinical Directions – polling resultsN Eng J Med2009360e14
   Web of Science ®Google Scholar
• SpatzESCanavanMEDesaiMMFrom here to JUPITER. Identifying new patients for statin therapy using data from the 1999–2004 National Health and Nutrition Examination SurveyCirc Qual Outcomes200924148
   PubMed Web of Science ®Google Scholar
• MichosEDBlumenthalRSPrevalence of the JUPITER (Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin) StudyJ Am Coll Cardiol20095393193519281922
   PubMed Web of Science ®Google Scholar
• RidkerPMThe JUPITER trial. Results, controversies, and implications for preventionCirc Cardiovasc Qual Outcomes2009227928520031849
   PubMed Web of Science ®Google Scholar
• RidkerPMMacFadyenJGFonsecaFAHJUPITER Study GroupNumber needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Justification for the Use of statins in Prevention: an Intervention Trial Evaluation Rosuvastatin (JUPITER)Circ Cardiovasc Qual Outcomes2009261662320031900
   PubMed Web of Science ®Google Scholar
• YangEYNambiVTangZClinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a US population: insights from the ARIC (Atherosclerosis Risk in Communities) studyJ Am Coll Cardiol2009542388239520082929
   PubMed Web of Science ®Google Scholar
• VaccarinoVBremmerJDKelleyMEJUPITER. A few words of cautionCirc Cardiovasc Qual Outcomes2009228628820031850
   PubMed Web of Science ®Google Scholar
• KonesRRecent advances in the management of chronic stable angina. II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularizationVasc Health Risk Manag2010674977420859545
   PubMedGoogle Scholar
• EyreHKahnRRobertsonRMPreventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart AssociationDiabetes Care2004271812182415220271
   PubMed Web of Science ®Google Scholar
• LeviJSegalLMJulianoCPrevention for a healthier America: investments in disease prevention yield significant savings, stronger communities: Trust for America’s Health Issue Report 2008 Jul. http://healthyamericans.org/reports/prevention08/Accessed 2010 Sep 1
   Google Scholar
• Heart Protection Study Collaborative GroupStatin cost-effectiveness in the United States for people at different vascular risk levelsCirc Cardiovasc Qual Outcomes20092657220031817
   PubMed Web of Science ®Google Scholar
• AccadMFredHLIs JUPITER also a God of primary preventionTex Heart Inst J2010376720200621
   PubMed Web of Science ®Google Scholar
• KappagodaCTAmsterdamEAAnother look at the results of the JUPITER trialAm J Cardiol20091041603160519932800
   PubMed Web of Science ®Google Scholar
• RidkerPMDanielsonEFonsecaFAReduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trialLancet20093731175118219329177
   PubMed Web of Science ®Google Scholar
• DespresJPBringing JUPITER down to EarthLancet20093731147114819329179
   PubMed Web of Science ®Google Scholar
• KostapanosMSMilionisHJElisafMSAn overview of the extra-lipid effects of rosuvastatinJ Cardiovasc Pharmacol Ther20081315717418460672
   PubMed Web of Science ®Google Scholar
• KendrickMShould women be offered cholesterol lowering drugs to prevent cardiovascular disease? NoBMJ200733498317494018
   PubMedGoogle Scholar
• EisenbergTWellsMStatins and adverse cardiovascular events in moderate-risk females: a statistical and legal analysis with implications for FDA preemption claimsJ Empir Leg Stud20085507550
   Web of Science ®Google Scholar
• RosenbergHAllardDWomen and statin use: a women’s health advocacy perspectiveScand Cardiovasc J20084226827318609063
   PubMed Web of Science ®Google Scholar
• MoraSGlynnRJHsiaJMacFadyenJGGenestJRidkerPMStatins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trialsCirculation20101211069107720176986
   PubMed Web of Science ®Google Scholar
• DuvernoyCSBlumenthalRThe numbers are in: statins for the primary prevention of cardiovascular disease in womenCirculation20101211063106520176993
   PubMed Web of Science ®Google Scholar
• Highlights of prescribing information: Crestor (rosuvastatin calcium) tablets http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021366s016lbl.pdfAccessed 2010 Apr 16
   Google Scholar
• KaulSMorrisseyRPDiamondGABy Jove! What is a clinician to make of JUPITERArch Int Med20101701073107720585074
   PubMed Web of Science ®Google Scholar
• Jupiter criticism addressed again in more detail2010101 http://www.theheart.org/article/1130113.doAccessed 2010 Oct 15
   Google Scholar
• BasslerDBrielMMontoriVMSTOPIT-2 Study GroupStopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysisJAMA20103031180118720332404
   PubMed Web of Science ®Google Scholar
• MontoriVMDevereauxPJAdhikariNKJRandomized trials stopped early for benefit: a systematic reviewJAMA20052942203220916264162
   PubMed Web of Science ®Google Scholar
• PocockSJCurrent controversies in data monitoring for clinical trialsClin Trials2006351352117170035
   PubMed Web of Science ®Google Scholar
• McCatneyMLeaping to conclusionsBMJ20083361213121418511794
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services, United States Food and Drug Administration, Center for Drug Evaluation and ResearchTranscript for the 2009 Dec 15, Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM200611.pdfAccessed 2010 Oct 7
   Google Scholar
• De LorgerilMSalenPAbramsonJCholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisalArch Intern Med20101701032103620585068
   PubMed Web of Science ®Google Scholar
• De LorgerilMAnswers to R. Ridker by M. de Lorgeril2010630 http://michel.delorgeril.info/dwnl/JUPITER/2010_Answers-to-Ridker-by-de-Lorgeril.pdfAccessed 2010 Aug 15
   Google Scholar
• GlynnRJDanielsonEFonsecaFAHA randomized trial of rosuvastatin in the prevention of venous thromboembolismN Engl J Med20093601851186119329822
   PubMed Web of Science ®Google Scholar
• RidkerPMMacfadyenJCressmanMGlynnRJEfficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention – an Intervention Trial Evaluating Rosuvastatin) trialJ Am Coll Cardiol2010551266127320206456
   PubMed Web of Science ®Google Scholar
• GlynnRJKoenigWNordestgaardBGShepherdJRidkerPMRosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trialAnn Intern Med2010152488496W17420404379
   PubMed Web of Science ®Google Scholar
• PearsonTAMensahGAAlexanderRWMarkers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart AssociationCirculation200310749951112551878
   PubMed Web of Science ®Google Scholar
• RidkerPMMacFadyenJGBørgeGNordestgaardBGRosuvastatin for primary prevention among individuals with elevated high-sensitivity C-reactive protein and 5% to 10% and 10% to 20% 10-year risk: implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial for “Intermediate Risk”Circ Cardiovasc Qual Outcomes2010344745220736443
   PubMed Web of Science ®Google Scholar
• KonesRRecent advances in the management of chronic stable angina I: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparitiesVasc Health Risk Manag2010663565620730020
   PubMedGoogle Scholar
• RidkerPMGlynnRJThe JUPITER Trial: Responding to the criticsAm J Cardiol20101061351135621029837
   PubMed Web of Science ®Google Scholar
• HarringtonRRidkerPMThe Bob Harrington ShowEpisode #26: Dissecting the controversy around JUPITER with Dr Paul Ridker http://radio.theheart.org/bob-harrington-show/2010/8/20/episode-26-dissecting-the-controversy-around-jupiter-with-dr-paul-ridker2010827
   Google Scholar
• http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM193831.pdf. (FDA memorandum, 2009 Nov 12, Appendix, page 11)Accessed 2010 Oct 7
   Google Scholar
• FriedlinBKornEStopping clinical trials early for benefit: impact on estimationClin Trials2009611912519342463
   PubMed Web of Science ®Google Scholar
• KornELFriedlinBMooneyMStopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Experience from 1990 to 2005J Clin Oncol2009271712172119237631
   PubMed Web of Science ®Google Scholar
• BruckertEHayemGDejagerSMild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients: the PRIMO studyCardiovasc Drugs Ther20051940341416453090
   PubMed Web of Science ®Google Scholar
• HsuISpinlerSAJohnsonNEComparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemiaAnn Pharmacother1995297437598520093
   PubMed Web of Science ®Google Scholar
• Garcia-RodriguezLAMasso-GonzalezELWallanderMAJohanssonSThe safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary carePharmacoepidemiol Drug Saf20081794395218425988
   PubMed Web of Science ®Google Scholar
• Garcia-RodriguezLAGonzalez-PerezAStangMRThe safety of rosuvastatin in comparison with other statins in over 25,000 statin users in the Saskatchewan Health DatabasesPharmacoepidemiol Drug Saf20081795396118425987
   PubMed Web of Science ®Google Scholar
• SukhijaRPrayagaSMarashdehMEffect of statins on fasting plasma glucose in diabetic and nondiabetic patientsJ Investig Med200957495499
   PubMed Web of Science ®Google Scholar
• KohKKQuonMJHanSHLeeYKimSJShinEKAtorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patientsJ Am Coll Cardiol2010551209121620298928
   PubMed Web of Science ®Google Scholar
• KostapanosMSMilionisHJAgouridisADRizosCVElisafMSRosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucoseInt J Clin Pract2009631308131319691613
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) CollaboratorsEfficacy of cholesterol-lowering therapy in 18,696 people with diabetes in 14 randomised trials of statins: a meta-analysisLancet200837111712518191683
   PubMed Web of Science ®Google Scholar
• SattarNPreissDMurrayHMStatins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsLancet201037573574220167359
   PubMed Web of Science ®Google Scholar
• BakerWLTalatiRWhiteCMColemanCIDiffering effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysisDiab Res Clin Pract20108798107
   PubMed Web of Science ®Google Scholar
• ZhangFLCaseyPJProtein prenylation: molecular mechanisms and functional consequencesAnnu Rev Biochem1996652412698811180
   PubMed Web of Science ®Google Scholar
• TakaiYSasakiTMatozakiTSmall GTP-binding proteinsPhysiol Rev20018115320811152757
   PubMed Web of Science ®Google Scholar
• GreenwoodJSteinmanLZamvilSSStatin therapy and autoimmune disease: from protein prenylation to immunomodulationNature Rev Immunol2006635837016639429
   PubMed Web of Science ®Google Scholar
• ChakrabartiREnglemanEGInterrelationships between mevalonate metabolism and the mitogenic signaling pathway in T lymphocyte proliferationJ Biol Chem199126612216122221712015
   PubMed Web of Science ®Google Scholar
• GrahamIAtarDBorch-JohnsenKFourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: executive summaryEur Heart J2007282375241417726041
   PubMed Web of Science ®Google Scholar
• LiuPYChenJHLinLJLiaoJKIncreased Rho kinase activity in a Taiwanese population with metabolic syndromeJ Am Coll Cardiol2007491619162417433952
   PubMed Web of Science ®Google Scholar
• LiaoJKDoes it matter whether or not a lipid-lowering agent inhibits Rho kinaseCurr Atheroscler Rep2007938438818001621
   PubMedGoogle Scholar
• DongMYanBPLiaoJKLamYYYipGWKYuCMRho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseasesDrug Discov Today20101562262920601092
   PubMed Web of Science ®Google Scholar
• BrozinickJTJrBerkemeierBAElmendorfJS“Acting” on GLUT 4: membrane and cytoskeletal components of insulin actionCurr Diabetes Rev2007311112218220662
   PubMedGoogle Scholar
• HorvathEMTackettLElmendorfJSA novel membrane-based anti-diabetic action of atorvastatinBiochem Biophys Res Commun200837263964318514061
   PubMed Web of Science ®Google Scholar
• NakataMNagasakaSKusakaIMatsuokaHIshibashiSYadaTEffects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycemic controlDiabetologia2006491881189216685502
   PubMed Web of Science ®Google Scholar
• WhiteCMA review of the pharmacologic and pharmacokinetic aspects of rosuvastatinJ Clin Pharmacol20024296397012211221
   PubMed Web of Science ®Google Scholar
• MitaTWatadaHNakayamaSPreferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemiaEndocr J20075444144717457013
   PubMed Web of Science ®Google Scholar
• YadaTNakataMShiraishiTKakeiMInhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signaling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet b-cellsBr J Pharmacol19991261205121310205010
   PubMed Web of Science ®Google Scholar
• SiddalsKWMarshmanEWestwoodMGibsonJMAbrogation of insulin-like growth factor-I (IGF-I) and insulin action by mevalonic acid depletion: synergy between protein prenylation and receptor glycosylation pathwaysJ Biol Chem2004279383533835915247258
   PubMed Web of Science ®Google Scholar
• OtokozawaSAiMvan HimbergenTEffects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levelsAtherosclerosis200920519720119200542
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of Medical Care in Diabetes – 2009Diabetes Care200932Suppl 1S136119118286
   PubMed Web of Science ®Google Scholar
• PasternakRCSmithSCBairey-MerzCNGrundySMCleemanJILenfantCACC/AHA/NHLBI clinical advisory on the use and safety of statinsStroke2002332337234112215610
   PubMed Web of Science ®Google Scholar
• ThompsonPDClarksonPKarasRHStatin-associated myopathyJAMA20032891681169012672737
   PubMed Web of Science ®Google Scholar
• TomlinsonSSMangioneKKPotential adverse effects of statins on musclePhys Ther20058545946515842193
   PubMed Web of Science ®Google Scholar
• SEARCH Collaborative GroupLinkEParishSArmitageJSLCO1B1 variants and statin-induced myopathy – a genomewide studyN Eng J Med2008359789799
   PubMed Web of Science ®Google Scholar
• GomesMDLeckerSHJagoeRTNavonAGoldbergALAtrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophyProc Natl Acad Sci U S A200198144401444511717410
   PubMed Web of Science ®Google Scholar
• HanaiJCaoPTanksalePThe muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicityJ Clin Invest20071173940395117992259
   PubMed Web of Science ®Google Scholar
• CaoPHanaiJ-iTanksalePImamuraSSukhatmeVPLeckerSHStatin-induced muscle damage and atrogin-1 induction is the result of a geranylgeranylation defectFASEB J2009232844285419406843
   PubMed Web of Science ®Google Scholar
• KnauerMJUrquhartBLMeyerzu SchwabedissenHEHuman skeletal muscle drug transporters determine local exposure and toxicity of statinsCirc Res201010629730619940267
   PubMed Web of Science ®Google Scholar
• DorajooRPereiraBPYuZRole of multidrug resistance-associated protein-1 transporter in statin-induced myopathyLife Sci20088282383018509883
   PubMed Web of Science ®Google Scholar
• MastersBAPalmoskiMJGlintOPGreggREWang-IversonDDurhamSKIn vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytesToxicol Appl Pharmacol19951311631747878672
   PubMed Web of Science ®Google Scholar
• Thalacker-MercerABakerMCalderonCBammanMSimvastatin Reduces Human Primary Satellite Cell Proliferation in CulturePresentation, American Physiological Society, The Integrative Biology of Exercise V2008 Sep 24–27Hilton Head, SC. http://www.the-aps.org/press/journal/08/32.htmand http://www.the-aps.org/Video/Clips/AnnaThalacker-Mercer.htmAccessed 2010 Nov 20
   Google Scholar
• MarcoffLThompsonPDThe role of coenzyme Q10 in statinassociated myopathy: a systematic reviewJ Am Coll Cardiol2007492231223717560286
   PubMed Web of Science ®Google Scholar
• DirksAJJonesKMStatin-induced apoptosis and skeletal myopathyAm J Physiol Cell Physiol2006291C1208121216885396
   PubMed Web of Science ®Google Scholar
• SirventPMercierJLacampagneANew insights into mechanisms of statin-associated myotoxicityCurr Opin Pharmacol2008833333818243052
   PubMed Web of Science ®Google Scholar
• NeedhamMFabianVKnezevicWProgressive myopathy with upregulation of MHC-I associated with statin therapyNeuromuscul Disord20071719420017241784
   PubMed Web of Science ®Google Scholar
• Grable-EspositoPKatzbergHDGreenbergSAImmune-mediated necrotizing myopathy associated with statinsMuscle Nerve20104118519019813188
   PubMed Web of Science ®Google Scholar
• VaklavasCChatzizisisYSZiakasAZamboulisCGiannoglouGDMolecular basis of statin-associated myopathyAtherosclerosis2009202182818585718
   PubMed Web of Science ®Google Scholar
• MasEMoriTACoenzyme Q10 and statin myalgia: what is the evidenceCurr Atheroscler Rep20101240741320725809
   PubMed Web of Science ®Google Scholar
• VandenbergBFRobinsonJManagement of the patient with statin intoleranceCurr Atheroscler Rep201012485720425271
   PubMed Web of Science ®Google Scholar
• MammenALAmatoAAStatin myopathy: a review of recent progressCurr Opin Rheumatol20102264465020827205
   PubMed Web of Science ®Google Scholar
• ThompsonPDClarksonPMRosensonRSAn assessment of statin safety by muscle expertsAm J Cardiol20069769C76C
   PubMed Web of Science ®Google Scholar
• ArmitageJThe safety of statins in clinical practiceLancet20073701781179017559928
   PubMed Web of Science ®Google Scholar
• FordESLiCZhaoGTsaiJTrends in obesity and abdominal obesity among adults in the United States from 1999–2008Int J Obes (Lond)201097 [Epub ahead of print]
   Web of Science ®Google Scholar
• FilionKBGenestJJosephLThe metabolic syndrome and cardiovascular risk: a systematic review and meta-analysisJ Am Coll Cardiol2010561113113220863953
   PubMed Web of Science ®Google Scholar
• DeMazumderDHasanRKBlumenthalRSMichosEDJonesSShould statin therapy be allocated on the basis of global risk or on the basis of randomized trial evidenceAm J Cardiol201010690590920816135
   PubMed Web of Science ®Google Scholar
• NambiVBallantyneCM“Risky Business”: ten years is not a lifetimeCirculation200911936236419171864
   PubMed Web of Science ®Google Scholar
• Lloyd-JonesDMHongYLabartheDAmerican Heart Association Strategic Planning Task Force and Statistics CommitteeDefining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyondCirculation201012158661320089546
   PubMed Web of Science ®Google Scholar
• WebsterRHeeleyEPerceptions of risk: understanding cardiovascular diseaseRisk Management and Healthcare Policy201034960
   PubMedGoogle Scholar